Janssen’s Spravato Enters US Market With Enhanced REMS And Plans For A Monotherapy Trial

 
• By Sue Sutter

Restrictive risk management plan for antidepressant nasal spray requires patients be monitored for two hours after dosing and enroll in a patient registry; Janssen has agreed to conduct a monotherapy efficacy trial as a postmarketing commitment.

Spravato manufacturing
Janssen is manufacturing Spravato in anticipation of a US roll-out starting in mid-March. • Source: Janssen

More from Approvals

More from Product Reviews